Amylyx Pharmaceuticals, Inc. (AMLX) Financials

AMLX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 264.6 million 25.4 million
March 31, 2026 293.6 million 20.4 million
Dec. 31, 2025 332.6 million 27.4 million
Sept. 30, 2025 362.7 million 30.7 million

AMLX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -31.5 million 8.3 million
March 31, 2026 -36.9 million 6.1 million
Dec. 31, 2025 -28.0 million 6.4 million
Sept. 30, 2025 -30.4 million 7.1 million

AMLX Net Income

No data available :(

AMLX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 250.8 million - 5.3 million
March 31, 2026 279.8 million 4.5 million 1.2 million
Dec. 31, 2025 317.0 million 4.7 million 1.3 million
Sept. 30, 2025 344.0 million - 5.0 million

AMLX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 111.2 million
March 31, 2026 110.6 million
Dec. 31, 2025 94.6 million
Sept. 30, 2025 93.3 million

AMLX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 30000 23.8 million 21.9 million -
March 31, 2026 - 27.6 million 16.2 million -
Dec. 31, 2025 86000 21.1 million 15.4 million -
Sept. 30, 2025 24000 19.9 million 16.2 million -

AMLX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 98000
Dec. 31, 2025 - 108000
Sept. 30, 2025 - 19.9 million

AMLX

Price: $21.63

52 week price:
7.48
24.60

Earnings Per Share: -1.47 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 390250

Market Capitalization: 2.6 billion

Links: